

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
14 April 2022 (14.04.2022)



(10) International Publication Number
WO 2022/076853 A1

(51) International Patent Classification:

A61K 47/60 (2017.01) C07K 16/28 (2006.01)
A61K 38/20 (2006.01) A61P 35/00 (2006.01)
A61K 39/395 (2006.01) A61P 37/04 (2006.01)

(21) International Application Number:

PCT/US2021/054225

(22) International Filing Date:

08 October 2021 (08.10.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/090,033	09 October 2020 (09.10.2020)	US
63/158,669	09 March 2021 (09.03.2021)	US
63/173,114	09 April 2021 (09.04.2021)	US

(71) Applicant: **SYNTHORX, INC.** [US/US]; 11099 North Torrey Pines Road, Suite 190, La Jolla, California 92037 (US).

(72) Inventors: **CAFFARO, Carolina E.**; c/o Sanofi, 55 Corporate Drive, Mail Code 55A-525, Bridgewater, New Jersey 08807 (US). **LEVEQUE, Joseph**; c/o Sanofi, 55 Corporate Drive, Mail Code 55A-525, Bridgewater, New Jersey 08807 (US). **MILLA, Marcos**; c/o Sanofi, 55 Corporate Drive, Mail Code 55A-525, Bridgewater, New Jersey 08807 (US).

rate Drive, Mail Code 55A-525, Bridgewater, New Jersey 08807 (US). **PTACIN, Jerod**; c/o Sanofi, 55 Corporate Drive, Mail Code 55A-525, Bridgewater, New Jersey 08807 (US). **SHAWVER, Laura**; c/o Sanofi, 55 Corporate Drive, Mail Code 55A-525, Bridgewater, New Jersey 08807 (US).

(74) Agent: **KUZELKA, Jane** et al.; McNeill Baur PLLC, 125 Cambridge Park Drive, Suite 301, Cambridge, Massachusetts 02140 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,

(54) Title: IMMUNO ONCOLOGY COMBINATION THERAPY WITH IL-2 CONJUGATES AND PEMBROLIZUMAB




FIG. 1A

CD8+ Effector T-Cell

(57) Abstract: Disclosed herein are methods for treating a cancer in a subject in need thereof, comprising administering IL-2 conjugates in combination with pembrolizumab.

WO 2022/076853 A1

[Continued on next page]

EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *with sequence listing part of description (Rule 5.2(a))*